Clinical efficacy of novel cancer vaccines

Clinical efficacy of novel cancer vaccines - Cancer vaccine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009167

Enrollment

100

Registered

2012-11-01

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incurable lung, esophageal, colorectal, gastric, gallbladder, or breast cancer

Interventions

cancer peptide vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically proven advanced or metastatic lung (NSCLC), esophageal, colorectal, gastric, gallbladder, or breast cancer 2) measurable lesions 3) HLA-A2402 4) withdrawn from previous treatments 5) Performance Status (P.S.) of 0-1 6) life expectancy of 3 months 7) preserved organ functions 8) written informed concent 9) no desire of pregnancy in female patients

Exclusion criteria

Exclusion criteria: 1) autoimmune disease 2) uncontrolled complications 3) pregnant 4) allergy of contrast enhancements 5) systemic symptom(s) of dyspnea, jaundice, edema, effusions, clamp, paralysis, fracture, or inpatients 6) double or more cancers 7) other active cancer treatment 8) steroids or immunosuppressants 9) anybody assessed as inappropriate

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
OS, RR, safety, immune responses	—

Countries

Japan

Contacts

Public ContactYosiyuki YAMAGUCHI

Kawasaki Medical School Department of Clinical Oncology

kasco@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026